Contemplating Alzheimer’s Disease and the Contribution of White Matter Hyperintensities
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
As the older adult segment of the population increases, Alzheimer’s disease (AD) has emerged as a significant public health epidemic. Over the past 3 decades, advances in the understanding of the biology of AD have led to a somewhat unified hypothesis of disease pathogenesis that emphasizes the precipitating role of beta amyloid protein. However, several lines of evidence suggest that multiple pathologies are necessary for clinical manifestation of the disease. Our focus over the past several years has been on the contribution of small vessel cerebrovascular disease, visualized as white matter hyperintensities (WMH) on magnetic resonance imaging, to AD. White matter hyperintensity volume, particularly in parietal regions, is elevated among individuals with and at risk for AD, predicts future diagnosis of AD, predicts the rate of progression of cognitive symptoms among individuals with AD, and increases over time among individuals destined to develop AD. White matter hyperintensities may represent an independent source of impairment and/or may interact more fundamentally with “primary” AD pathology. Future work should focus on more inclusive models of that better define “normal” vs “pathological” aging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“Mild cognitive impairment due to AD is defined as evidence of cognitive impairment in the absence of functional decline and supported by presence of AD-related biomarkers [4].”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“evidence of an AD biomarker, such beta amyloid or hyperphosphorylated tau protein, in the absence of clinical symptomatology [3].”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Silent Brain Infarcts and the Risk of Dementia and Cognitive Decline
Vermeer, S. E., Prins, N. D., den Heijer, T., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022066 · Cited by 2,313
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Pathologic correlates of incidental MRI white matter signal hyperintensities
Fazekas, F., Kleinert, R., Offenbacher, H., Schmidt, R., Kleinert, G., Payer, F., Radner, H., & Lechner, H. (1993) · Neurology · doi:10.1212/wnl.43.9.1683 · Cited by 1,619
Research works printed but not linked: 51
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44. · DOI · Paper page
- McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2010;7:263–9. · DOI · Paper page
- Sperling R, Donohue M, Aisen P. The A4 trial: anti-amyloid treatment of asymptomatic Alzheimer’s disease. Alzheimers Dement. 2012;8(Suppl):425–6. · doi:10.1016/j.jalz.2012.05.1134
- Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509–17. · DOI · Paper page
- Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132(Pt 5):1310–23. · DOI · Paper page
- Brickman AM, Stern Y, Small SA. Hippocampal subregions differentially associate with standardized memory tests. Hippocampus. 2011;21:923–8. · DOI · Paper page
- Castellani RJ, Perry G. Pathogenesis and disease-modifying therapy in Alzheimer’s disease: the flat line of progress. Arch Med Res. 2012;43:694–8. · DOI
- Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre. Brain. 2013;136(Pt 9):2697–706. · DOI · Paper page
- Elkins JS, O’Meara ES, Longstreth Jr WT, Carlson MC, Manolio TA, Johnston SC. Stroke risk factors and loss of high cognitive function. Neurology. 2004;63:793–9. · DOI · Paper page
- Luchsinger JA, Patel B, Tang MX, Schupf N, Mayeux R. Measures of adiposity and dementia risk in elderly persons. Arch Neurol. 2007;64:392–8. · DOI · Paper page
- Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 2005;65:545–51. · DOI · Paper page
- Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology. 2004;63:1187–92. · DOI · Paper page
- Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. 2001;154:635–41. · DOI · Paper page
- Swan GE, DeCarli C, Miller BL, Reed T, Wolf PA, Jack LM, et al. Association of midlife blood pressure to late-life cognitive decline and brain morphology. Neurology. 1998;51:986–93. · DOI · Paper page
- Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol. 2009;66:343–8. · DOI · Paper page
- Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011;10:819–28. · DOI · Paper page
- Kertesz A, Black SE, Tokar G, Benke T, Carr T, Nicholson L. Periventricular and subcortical hyperintensities on magnetic resonance imaging. Rims, caps, and unidentified bright objects. Arch Neurol. 1988;45:404–8. Arch Neurol. 1988;45:404–8. · DOI · Paper page
- Bronge L, Wahlund LO. White matter changes in dementia: does radiology matter? Br J Radiol. 2007;80:S115–20. · DOI
- Erten-Lyons D, Woltjer R, Kaye J, Mattek N, Dodge HH, Green S, et al. Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology. 2013;81:977–83. · DOI · Paper page
- Launer LJ. Epidemiology of white matter lesions. Top Magn Reson Imaging. 2004;15:365–7. · DOI · Paper page
- Brickman AM, Muraskin J, Zimmerman ME. Structural neuroimaging in Alzheimer’s disease: do white matter hyperintensities matter? Dialog Clin Neurosci. 2009;11:181–90. · DOI · Paper page
- Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJ, Vermersch P, et al. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci. 1993;114:7–12. · DOI · Paper page
- Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR. 1987;149:351–6. · DOI · Paper page
- Brickman AM, Sneed JR, Provenzano FA, Garcon E, Johnert L, Muraskin J, et al. Quantitative approaches for assessment of white matter hyperintensities in elderly populations. Psychiatry Res. 2011;193:101–6. · DOI
- Tang MX, Cross P, Andrews H, Jacobs DM, Small S, Bell K, et al. Incidence of Alzheimer’s disease in African-Americans, Caribbean Hispanics and Caucasians in northern Manhattan. Neurology. 2001;56:49–56. · DOI · Paper page
- Brickman AM, Schupf N, Manly JJ, Luchsinger JA, Andrews H, Tang MX, et al. Brain morphology in older African Americans, Caribbean Hispanics, and Whites from northern Manhattan. Arch Neurol. 2008;65:1053–61. · DOI · Paper page
- Kalaria RN. The role of cerebral ischemia in Alzheimer’s disease. Neurobiol Aging. 2000;21:321–30. · DOI · Paper page
- Luchsinger JA, Brickman AM, Reitz C, Cho SJ, Schupf N, Manly JJ, et al. Subclinical cerebrovascular disease in mild cognitive impairment. Neurology. 2009;73:450–6. · DOI · Paper page
- Gootjes L, Teipel SJ, Zebuhr Y, Schwarz R, Leinsinger G, Scheltens P, et al. Regional distribution of white matter hyperintensities in vascular dementia, Alzheimer’s disease and healthy aging. Demen Geriat Cognit Dis. 2004;18:180–8. · DOI · Paper page
- Leys D, Pruvo JP, Parent M, Vermersch P, Soetaert G, Steinling M, et al. Could Wallerian degeneration contribute to “leuko-araiosis” in subjects free of any vascular disorder? J Neurol Neurosurg Psychiatry. 1991;54:46–50. · DOI · Paper page
- Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, et al. Cerebral white matter lesions and the risk of dementia. Arch Neurol. 2004;61:1531–4. · DOI · Paper page
- Wolf H, Ecke GM, Bettin S, Dietrich J, Gertz HJ. Do white matter changes contribute to the subsequent development of dementia in patients with mild cognitive impairment? A longitudinal study. Int J Geriat Psychiat. 2000;15:803–12. · DOI · Paper page
- Smith EE, Egorova S, Blacker D, Killiany RJ, Muzikansky A, Dickerson BC, et al. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Arch Neurol. 2008;65:94–100. · DOI · Paper page
- Brickman AM, Provenzano FA, Muraskin J, Manly JJ, Blum S, Apa Z, et al. Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol. 2012;69:1621–7. · DOI · Paper page
- Brickman AM, Honig LS, Scarmeas N, Tatarina O, Sanders L, Albert MS, et al. Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch Neurol. 2008;65:1202–8. · DOI · Paper page
- Wiegman AF, Meier IB, Provenzano FA, Schupf N, Manly JJ, Stern Y, et al. Regional white matter hyperintensity volume and cognition predict death in a multi-ethnic, community cohoort of older adults. J Am Geriatr Soc. 2013. · DOI
- Brickman AM, Reitz C, Luchsinger JA, Manly JJ, Schupf N, Muraskin J, et al. Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort. Arch Neurol. 2010;67:564–9. · DOI · Paper page
- Alosco ML, Brickman AM, Spitznagel MB, Griffith EY, Narkhede A, Raz N, et al. Independent and interactive effects of blood pressure and cardiac function on brain volume and white matter hyperintensities in heart failure. J Am Soc Hypertens. 2013;7:336–43. · DOI
- Portet F, Brickman AM, Stern Y, Scarmeas N, Muraskin J, Provenzano FA, et al. Metabolic syndrome and localization of white matter hyperintensities in the elderly population. Alzheimers Dement. 2012;8(5 Suppl):S88–95 e1. · DOI
- Brickman AM, Zahra A, Muraskin J, Steffener J, Holland CM, Habeck C, et al. Reduction in cerebral blood flow in areas appearing as white matter hyperintensities on magnetic resonance imaging. Psychiatry Res. 2009;172:117–20. · DOI · Paper page
- Holland CM, Smith EE, Csapo I, Gurol ME, Brylka DA, Killiany RJ, et al. Spatial distribution of white-matter hyperintensities in Alzheimer disease, cerebral amyloid angiopathy, and healthy aging. Stroke. 2008;39:1127–33. · DOI · Paper page
- Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C. Cerebral auotregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol. 2002;283:H315–23. · DOI · Paper page
- Roher AE, Kuo YM, Esh C, Knebel C, Weiss N, Kalback W, et al. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer’s disease. Mol Med. 2003;9:112–22. · DOI · Paper page
- Weller RO, Cohen NR, Nicoll JA. Cerebrovascular disease and the pathophysiology of Alzheimer’s disease. Implications for therapy. Panminerva Med. 2004;46:239–51.
- Preston SD, Steart PV, Wilkinson A, Nicoll JA, Weller RO. Capillary and arterial cerebral amyloid angiopathy in Alzheimer’s disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol Appl Neurobiol. 2003;29:106–17. · DOI · Paper page
- Maia LF, Vasconcelos C, Seixas S, Magalhaes R, Correia M. Lobar brain hemorrhages and white matter changes: clinical, radiological and laboratorial profiles. Cerebrovasc Dis. 2006;22:155–61. · DOI
- Chen YW, Gurol ME, Rosand J, Viswanathan A, Rakich SM, Groover TR, et al. Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy. Neurology. 2006;67:83–7. · DOI · Paper page
- Pettersen JA, Sathiyamoorthy G, Gao FQ, Szilagyi G, Nadkarni NK, St George-Hyslop P, et al. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch Neurol. 2008;65:790–5. · DOI · Paper page
- Meier IB, Narkhede A, Provenzano FA, Luchsinger JA, Manly JJ, Willey JZ, et al. Lobar microbleeds are associated with white matter hyperintensities and memory in older adults [abstract]. J Int Neuropsychol Soc. 2012;18:224–5.
- Guzman VA, Carmichael OT, Schwarz C, Tosto G, Zimmerman ME, Brickman AM, et al. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume. Alzheimer’s and Dementia. 2013;9:S124–31. · DOI · Paper page
- van der Flier WM, Barkhof F, Scheltens P. Shifting paradigms in dementia: toward stratification of diagnosis and treatment using MRI. Ann NY Acad Sci. 2007;1097:215–24. · DOI
Cited by
White matter changes in Alzheimer’s disease: A focus on myelin and oligodendrocytes
Nasrabady, S. E., Rizvi, B., Goldman, J. E., & Brickman, A. M. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0515-3 · Cited by 723
“[18, 19, 21], the rate of cognitive decline among individuals with prevalent AD [78], and is associated with genetic risk factors for late onset AD [20].”
Self-citationLee, S., Viqar, F., Zimmerman, M. E., Narkhede, A., Tosto, G., Benzinger, T. L. S., Marcus, D. S., Fagan, A. M., Goate, A., Fox, N. C., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24647 · Cited by 542
“In recent years, there has been strong evidence that WMHs are associated with the clinical risk and symptomatic course of late-onset Alzheimer’s disease (LOAD).(3) Despite these consistent observations, white matter abnormalities are not included in current conceptual models of the pathogenesis and biological marker p…”
Babulal, G. M., Quiroz, Y. T., Albensi, B. C., Arenaza‐Urquijo, E., Astell, A. J., Babiloni, C., Bahar‐Fuchs, A., Bell, J., Bowman, G. L., Brickman, A. M., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.009 · Cited by 528
Self-citationAgeing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
White matter and cognition: making the connection
Filley, C. M., & Fields, R. D. (2016) · Journal of Neurophysiology · doi:10.1152/jn.00221.2016 · Cited by 443
Metadata
- Authors
- Brickman, A. M.
- Venue
- Current Neurology and Neuroscience Reports
- Published
- 2013-11-05
- Volume
- 13
- Issue
- 12
- Pages
- 415-415
- ISSN
- 1528-4042 (ISSN-L)
- 1534-6293
- OpenAlex
- W1969443632
- Cited by
- 141
- References
- 41
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Contemplating Alzheimer’s Disease and the Contribution of White Matter Hyperintensities. https://app.cochat.ai/papers/10.1007/s11910-013-0415-7
- The paper
- Brickman, A. M. (2013). Contemplating Alzheimer’s Disease and the Contribution of White Matter Hyperintensities. Current Neurology and Neuroscience Reports. https://doi.org/10.1007/s11910-013-0415-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.